Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.

Study Overview

• Status: Completed
• Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
• Intervention / Treatment: Drug: secukinumab 150 mg

Detailed Description

A 52-week multicenter, randomized, double-blind, parallel-group trial in 331 subjects with moderate to severe chronic plaque-type psoriasis of body weight 90 kg or higher at time of randomization.

This study consisted of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks), treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).

Subjects were randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every 2 weeks; Secukinumab 300 mg every 4 weeks.

In addition, subjects from the 300 mg every 4 weeks group who did not achieve Psoriasis Area Severity Index (PASI) 90 response at Week 16 were reassigned using a 1:1 ratio to either remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks starting at Week 16, until the end of treatment.

• Study Type: Interventional
• Enrollment (Actual): 331
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Quebec, Canada, G1V 4X7
    • Novartis Investigative Site
  • Alberta
    • Calgary, Alberta, Canada, T2G 1B1
      • Novartis Investigative Site
    • Red Deer, Alberta, Canada, T4N 6V7
      • Novartis Investigative Site
  • Ontario
    • Etobicoke, Ontario, Canada, M8X 1Y9
      • Novartis Investigative Site
    • Guelph, Ontario, Canada, N1L 0B7
      • Novartis Investigative Site
    • Hamilton, Ontario, Canada, L8N 1V6
      • Novartis Investigative Site
• Czechia
  • Novy Jicin, Czechia, 741 01
    • Novartis Investigative Site
  • Prague 1
    • Prague, Prague 1, Czechia, 11000
      • Novartis Investigative Site
• Germany
  • Bochum, Germany, 44793
    • Novartis Investigative Site
  • Frankfurt, Germany, 60590
    • Novartis Investigative Site
  • Hamburg, Germany, 20246
    • Novartis Investigative Site
  • Hamburg, Germany, 20537
    • Novartis Investigative Site
  • Kiel, Germany, 24105
    • Novartis Investigative Site
  • Leipzig, Germany, 04103
    • Novartis Investigative Site
• Hungary
  • Debrecen, Hungary, 4032
    • Novartis Investigative Site
  • Pecs, Hungary, 7623
    • Novartis Investigative Site
  • Szeged, Hungary, H 6725
    • Novartis Investigative Site
• Italy
  • Napoli, Italy, 80138
    • Novartis Investigative Site
  • MI
    • Rozzano, MI, Italy, 20089
      • Novartis Investigative Site
  • MO
    • Modena, MO, Italy, 41124
      • Novartis Investigative Site
  • PG
    • Perugia, PG, Italy, 06100
      • Novartis Investigative Site
  • SI
    • Siena, SI, Italy, 53100
      • Novartis Investigative Site
• Russian Federation
  • Chelyabinsk, Russian Federation, 454092
    • Novartis Investigative Site
  • Ekaterinburg, Russian Federation, 620023
    • Novartis Investigative Site
  • Kazan, Russian Federation, 420012
    • Novartis Investigative Site
  • Krasnodar, Russian Federation, 350020
    • Novartis Investigative Site
  • Lipetsk, Russian Federation, 398005
    • Novartis Investigative Site
  • Saint Petersburg, Russian Federation, 197022
    • Novartis Investigative Site
  • Saratov, Russian Federation, 410012
    • Novartis Investigative Site
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35205
      • Novartis Investigative Site
  • Arizona
    • Phoenix, Arizona, United States, 85032
      • Novartis Investigative Site
  • Arkansas
    • Rogers, Arkansas, United States, 72758
      • Novartis Investigative Site
  • California
    • Irvine, California, United States, 92697
      • Novartis Investigative Site
    • Sacramento, California, United States, 95817
      • Novartis Investigative Site
    • Sacramento, California, United States, 95819
      • Novartis Investigative Site
    • San Diego, California, United States, 92123
      • Novartis Investigative Site
    • Santa Monica, California, United States, 90404
      • Novartis Investigative Site
  • Colorado
    • Centennial, Colorado, United States, 80111
      • Novartis Investigative Site
  • Florida
    • Tampa, Florida, United States, 33612
      • Novartis Investigative Site
    • West Palm Beach, Florida, United States, 33409
      • Novartis Investigative Site
  • Georgia
    • Alpharetta, Georgia, United States, 30022
      • Novartis Investigative Site
    • Snellville, Georgia, United States, 30078
      • Novartis Investigative Site
  • Illinois
    • Skokie, Illinois, United States, 60077
      • Novartis Investigative Site
  • Indiana
    • Indianapolis, Indiana, United States, 46256
      • Novartis Investigative Site
    • New Albany, Indiana, United States, 47150
      • Novartis Investigative Site
  • Kentucky
    • Louisville, Kentucky, United States, 40241
      • Novartis Investigative Site
    • Owensboro, Kentucky, United States, 42303
      • Novartis Investigative Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Novartis Investigative Site
  • Minnesota
    • New Brighton, Minnesota, United States, 55112
      • Novartis Investigative Site
  • Missouri
    • Saint Joseph, Missouri, United States, 64506
      • Novartis Investigative Site
  • New Jersey
    • East Windsor, New Jersey, United States, 08520
      • Novartis Investigative Site
    • Verona, New Jersey, United States, 07044
      • Novartis Investigative Site
  • New York
    • Forest Hills, New York, United States, 11375
      • Novartis Investigative Site
    • New York, New York, United States, 10025 1737
      • Novartis Investigative Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28277
      • Novartis Investigative Site
    • Winston-Salem, North Carolina, United States, 27157
      • Novartis Investigative Site
  • Ohio
    • Fairborn, Ohio, United States, 45324
      • Novartis Investigative Site
  • Oregon
    • Oregon City, Oregon, United States, 97045
      • Novartis Investigative Site
    • Portland, Oregon, United States, 97210
      • Novartis Investigative Site
  • South Carolina
    • Charleston, South Carolina, United States, 29414
      • Novartis Investigative Site
  • Texas
    • Houston, Texas, United States, 77056
      • Novartis Investigative Site
    • Mesquite, Texas, United States, 75150
      • Novartis Investigative Site
    • Pflugerville, Texas, United States, 78660
      • Novartis Investigative Site
    • San Antonio, Texas, United States, 78218
      • Novartis Investigative Site
  • Virginia
    • Norfolk, Virginia, United States, 23507
      • Novartis Investigative Site
  • Washington
    • Wenatchee, Washington, United States, 98801
      • Novartis Investigative Site
  • Wisconsin
    • Madison, Wisconsin, United States, 53717
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Written informed consent must have been obtained before any assessment was performed. Where relevant, a legal representative will also have signed the informed study consent according to local laws and regulations.
• Subjects must have been able to understand and communicate with the investigator and comply with the requirements of the study.
• Men or women at least 18 years of age at time of screening.
• Body weight of ≥ 90 kg at the time of randomization.
• Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization.

• Moderate to severe psoriasis as defined at randomization by:

  • Psoriasis Area and Severity Index (PASI) score of 12 or greater, and
  • Investigator's Global Assessment (IGA) mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and
  • Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.

• Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by:

  • topical treatment and/or,
  • phototherapy and/or,
  • previous systemic therapy.

Key Exclusion Criteria:

• Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at screening or Randomization.
• Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to. Subjects not willing to limit ultraviolet (UV) light exposure (e.g., sunbathing and / or the use of tanning devices) during the course of the study will be considered not eligible for this study since UV light exposure is prohibited. Note: administration of live vaccines 6 weeks prior to Randomization or during the study period is also prohibited.
• Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting Interleukin-17 (IL-17) or the IL-17 receptor.
• Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 4 weeks until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
• Pregnant or nursing (lactating) women
• History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
• History of hypersensitivity to any of the study drug constituents.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Secukinumab 300 mg every 2 weeks (Q2W); 2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.	Drug: secukinumab 150 mg; sub-cutaneous secukinumab prefilled syringe 150 mg
Active Comparator: Secukinumab 300 mg every 4 weeks (Q4W); 2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.	Drug: secukinumab 150 mg; sub-cutaneous secukinumab prefilled syringe 150 mg
Active Comparator: Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up); 2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).	Drug: secukinumab 150 mg; sub-cutaneous secukinumab prefilled syringe 150 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)	A subject was considered as a PASI 90 responder if s/he achieved a reduction of 90% or more of the PASI score, compared to baseline, at a given time point.The head, trunk, upper limbs and lower limbs were assessed separately for erythema, thickening, and scaling. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0, i.e., higher scores represent more severity.	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)	IGA mod 2011 was conducted for overall psoriatic disease. The IGA modified 2011 used in this study was static, i.e., it referred exclusively to the subject's disease state at the time of the assessments, and did not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit. The scale has 0 (clear) as min and 4 (severe) as max, i.e., a higher score indicates more severity.	16 weeks
Absolute and Relative Frequencies for Deaths, Other Serious or Clinically Significant Adverse Events or Related Discontinuations - Entire Study Period (Safety Set)	An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.	Adverse events were reported from first dose of study treatment until end of study treatment plus 8 weeks post treatment, up to a maximum timeframe of 470 days.

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Publications and helpful links

General Publications

• Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8.

Helpful Links

• A Plain Language Trial Summary is available on novartisclinicaltrials.com

Study record dates

Study Major Dates

• Study Start (Actual): June 25, 2018
• Primary Completion (Actual): September 13, 2019
• Study Completion (Actual): July 15, 2020

Study Registration Dates

• First Submitted: March 29, 2018
• First Submitted That Met QC Criteria: April 12, 2018
• First Posted (Actual): April 20, 2018

Study Record Updates

• Last Update Posted (Actual): October 11, 2021
• Last Update Submitted That Met QC Criteria: October 7, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: plaques; psoriasis; weight; itching; immune-mediated systemic disease; papules; secukinumab
• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: CAIN457A2324; 2015-004620-60 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes

IPD Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No